DSIP news and clinical trials
Also known as: Delta sleep-inducing peptide · Emideltide · Emideltide acetate · Deltaran
Updated 72 sources
1 new study and 1 regulatory action in the last 12 months, newest first: trial registrations and results, PubMed papers, FDA actions and press coverage that name DSIP. Each line links to the primary source.
April 2026
- RegulatoryFederal RegisterPharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List (opens Federal Register)
The FDA announced a public advisory committee meeting of the Pharmacy Compounding Advisory Committee to seek input on bulk drug substances nominated for the Section 503A bulk drug substances list.
NoticeFood and Drug Administration2026-07361
January 2026
- StudyPubMedTherapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions (opens PubMed)
A review published in the Journal of the American Academy of Orthopaedic Surgeons analyzed the use of therapeutic peptides in orthopaedics. The authors noted that while peptides show promise in preclinical models for tissue regeneration, there is currently a lack of clinical trials.
Journal of the American Academy of Orthopaedic Surgeons. Global research & reviewsReviewPMID 41490200
Searched as: DSIP, Delta sleep-inducing peptide, Emideltide, Deltaran. Summaries are one or two sentences, published only when every number in them appears in the source record. A tracker, not medical advice.